The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.
Ironwood Pharmaceuticals has announced the initiation of a New Drug Application (NDA) submission for apraglutide for the treatment of short bowel syndrome (SBS) who are dependent on parenteral support.1
Mike Shetzline, MD, PhD
Credit: Ironwood Pharmaceuticals
According to a January 29, 2025, release, in addition to initiating a rolling NDA submission, the company plans to announce new data from its open-label extension study, STARS Extend, demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time. Of note, this long-term extension data will be included in the NDA, along with efficacy and tolerability data from STARS.1
“With these new data, we are even more encouraged about apraglutide’s potential to help SBS patients who are dependent on parenteral support,” said Mike Shetzline, MD, PhD, chief medical officer, senior vice president, and head of research and drug development at Ironwood.1
Data from the multicenter, double-blind, randomized, placebo-controlled phase 3 STARS trial were presented during a late-breaking session at Digestive Disease Week (DDW) 2024 in Washington, DC, and showed significantly more patients treated with apraglutide gained additional days off from parenteral support per week and were clinical responders or clinical high responders, building upon previous positive topline data announced earlier in 2024. It was conducted in 18 countries with enrollment from 68 study sites and is the largest global SBS-IF clinical trial to date, involving a total of 164 patients who were randomly assigned in a 2:1 ratio to receive once weekly apraglutide or placebo, stratified by remnant bowel anatomy, and evaluated over 24- and 48-week periods.2
Ironwood previously reported the STARS trial met its primary endpoint of relative change from baseline in actual weekly parenteral support volume at week 24 compared to placebo (-25.5% vs -12.5%; P = .001), driven by both stoma and colon-in-continuity subpopulations. Additionally, treatment effect with relative parenteral support volume reduction was observed from week 8 onward (-8% vs -1.6%; P = .002).1
Data presented at DDW showed significantly more apraglutide patients gained additional days off from parenteral support per week at week 24 versus placebo (≥ 2 days, 24.5% vs 11.3%; P = .021 and ≥ 3 days, 11.8% vs 1.9%; P = .006). Additionally, significantly more patients treated with apraglutide were clinical responders and clinical high responders, defined as ≥20% and ≥40% parenteral support volume reduction, respectively, at both weeks 20 and 24 versus placebo.1
Of note, in order to position the company for long-term growth with apraglutide, Ironwood announced plans to reduce its workforce by approximately 50%.1
“Ironwood’s long track record of success stems from our ability to be nimble as an organization by focusing on both significant medical needs and financial performance. While LINZESS continues to grow prescription demand, given the impact of ongoing pricing pressures, we are taking steps to reduce Ironwood costs that are predominantly associated with the brand. By doing so, we believe we can continue to generate profits and cash flows and support the successful development of apraglutide,” said Tom McCourt, chief executive officer of Ironwood, who added that the company’s apraglutide launch planning is “well underway” with “strong commercial capabilities to support the future success of apraglutide, if approved.”
References
The Hidden Connection Between Air Quality and Gut Health
April 21st 2025Long-term exposure to multiple air pollutants may silently wreak havoc on your gut, significantly increasing the risk of gastrointestinal diseases and underscoring the urgent need for public health policies that clean the air we breathe and protect our digestive health.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
How Does Diet Influence GI Cancer Outcomes?
April 16th 2025Healthy dietary patterns, rich in fruits, vegetables, whole grains, and legumes, may significantly reduce the risk and mortality of gastrointestinal cancers, while diets high in red and processed meats, alcohol, and sugary beverages can increase these risks.
Read More
The Future of GI Drug Delivery in Managing IBD
April 10th 2025New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential for enhancing targeted treatment and sustained release of medications in the gastrointestinal (GI) tract, particularly for managing inflammatory bowel disease (IBD).
Read More
Vedolizumab First Shows Clinical and Economic Advantage in Ulcerative Colitis
April 8th 2025Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative colitis and Crohn disease, and was less costly in ulcerative colitis, according to a real-world economic analysis from the EVOLVE study.
Read More